Business, energy, technology, markets and global industry news from Business News Today

Neuphoria Therapeutics

PharmaDeviceNews Neuphoria Therapeutics
Representative image: Corporate and clinical teams review melanoma trial data as Scancell moves to acquire Neuphoria Therapeutics $NEUP and secure up to $89 million to fund the Phase 3 iSCIB1+ immunotherapy program.
Pharma & Biotech

Scancell secures path to $89m financing through Neuphoria Therapeutics merger

Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.

Read More